



Small Business Innovation Research (SBIR)
Small Business Technology Transfer (STTR)

National Institutes of Health
Commercialization Assistance Program (NIH CAP)



For-Robin, Inc.



Contact:
Kate Rittenhouse-Olson

Location:
Buffalo, NY

Email:
krolson@for-robin.com

Tel:
716.866.6941

Website:
<http://www.for-robin.com>



Company Profile

Industry Sector: Biotechnology/Oncology

Company Overview: For-Robin, Inc, founded in 2012 and named in honor of the founder's sister who died at age 31 of breast cancer (BrCa), is an antibody immunotherapy company whose primary mission is developing treatments for BrCa patients. Our proprietary technology (monoclonal antibody, JAA-F11 and humanized variants, hJAA-F11) targets all BrCa cell subtypes including triple negative BrCa where no targeted therapy currently exists. For-Robin is developing hJAA-F11 for adjunct therapy of BrCa either directly or as antibody-drug conjugates.

Target Market(s): Major Pharmaceutical Companies



Key Value Drivers

Technology*: Our patented technology, JAA-F11 specifically targets the alpha-linked form of a well-known disaccharide tumor marker, the Thomsen-Friedenreich glycoantigen (TF-Ag), found on the surface of 80% of all carcinomas

Competitive Advantage: : Our technology, the JAA-F11 antibody, is a targeted immunotherapy addressing the critical need for safe and effective treatment for primary and metastatic BrCa, including the unmet need for treatment of triple negative BrCa.

Plan & Strategy: Our strategic plan is to bring humanized JAA-F11 to first-in human BrCa trial and seek strategic pharmaceutical partnerships with the intent to license our technology.



Management

Leadership:

Kate Rittenhouse Olson, PhD, SI, ASCP, President
James Olson, PhD, Chairman/VP
Sally Quataert, PhD, RQAP-GLP, CEO

Scientific Advisory Board:

Steven Gorfien, Ph.D., Sr. Dir. Life Technologies
Donna Martin, MS, MBA, CLP, VP, Sanofi-Pasteur
Christopher P. Chengelis, Ph.D. D.A.B.T. Wil Research
Jack Derby, founder of Derby Management



Product Pipeline

1. Pipeline One: Humanized JAA-F11 for direct antibody therapy of Breast Cancer

2. Pipeline Two: Humanized JAA-F11 construct for antibody-drug conjugate delivery for Breast Cancer Therapy

3. Pipeline Three: Theranostic for IHC confirmation of TF-Ag expression prior to patient treatment with JAA-F11 therapy.